EMA Recommends Extension of Therapeutic Indications for Lisocabtagene Maraleucel
New indication concerns treatment of adult patients with DLBCL, HGBCL, PMBCL and FL3B, who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy